<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:47:10Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8905697" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8905697</identifier>
        <datestamp>2022-03-09</datestamp>
        <setSpec>bloodadv</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Blood Adv</journal-id>
              <journal-id journal-id-type="iso-abbrev">Blood Adv</journal-id>
              <journal-id journal-id-type="hwp">bloodoa</journal-id>
              <journal-id journal-id-type="publisher-id">Blood Advances</journal-id>
              <journal-title-group>
                <journal-title>Blood Advances</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2473-9529</issn>
              <issn pub-type="epub">2473-9537</issn>
              <publisher>
                <publisher-name>American Society of Hematology</publisher-name>
                <publisher-loc>Washington, DC</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8905697</article-id>
              <article-id pub-id-type="pmcid">PMC8905697</article-id>
              <article-id pub-id-type="pmc-uid">8905697</article-id>
              <article-id pub-id-type="pmid">35100339</article-id>
              <article-id pub-id-type="pmid">35100339</article-id>
              <article-id pub-id-type="publisher-id">2022/ADV2021005941</article-id>
              <article-id pub-id-type="doi">10.1182/bloodadvances.2021005941</article-id>
              <article-categories>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>20</subject>
                  <subject>23</subject>
                  <subject>24</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Trials and Observations</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0469-839X</contrib-id>
                  <name>
                    <surname>Chung</surname>
                    <given-names>David J.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff"/>
                  <xref rid="aff3" ref-type="aff"/>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sharma</surname>
                    <given-names>Sneh</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5825-2775</contrib-id>
                  <name>
                    <surname>Rangesa</surname>
                    <given-names>Madhumitha</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2754-3537</contrib-id>
                  <name>
                    <surname>DeWolf</surname>
                    <given-names>Susan</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4354-8864</contrib-id>
                  <name>
                    <surname>Elhanati</surname>
                    <given-names>Yuval</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Perica</surname>
                    <given-names>Karlo</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0032-6559</contrib-id>
                  <name>
                    <surname>Young</surname>
                    <given-names>James W.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff"/>
                  <xref rid="aff3" ref-type="aff"/>
                  <xref rid="aff4" ref-type="aff">4</xref>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label>Laboratory of Cellular Immunobiology, Sloan Kettering Institute for Cancer Research, New York, NY;</aff>
              <aff id="aff2"><label>2</label>Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;</aff>
              <aff id="aff3"><label>3</label>Department of Medicine, Weill Cornell Medical College, New York, NY;</aff>
              <aff id="aff4"><label>4</label>The Rockefeller University, New York, NY;</aff>
              <aff id="aff5"><label>5</label>Leukemia Service, Department of Medicine,</aff>
              <aff id="aff6"><label>6</label>Department of Epidemiology and Biostatistics, and</aff>
              <aff id="aff7"><label>7</label>Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; and</aff>
              <aff id="aff8"><label>8</label>Immunology Program, Sloan Kettering Institute for Cancer Research, New York, NY</aff>
              <author-notes>
                <fn id="FM1" fn-type="other">
                  <p>Requests for data sharing may be submitted to  David J. Chung (chungd1@mskcc.org).</p>
                </fn>
                <corresp id="cor1">Correspondence: David J. Chung, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; e-mail: <email xlink:href="mailto:chungd1@mskcc.org">chungd1@mskcc.org</email>.</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <day>8</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>4</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <volume>6</volume>
              <issue>5</issue>
              <fpage>1547</fpage>
              <lpage>1558</lpage>
              <history>
                <date date-type="received">
                  <day>20</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>03</day>
                  <month>1</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted-manuscript">
                  <day>31</day>
                  <month>1</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2022 by The American Society of Hematology. Licensed under <ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode" ext-link-type="uri">Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)</ext-link>, permitting only noncommercial, nonderivative use with attribution. All other rights reserved.</copyright-statement>
                <copyright-year>2022</copyright-year>
              </permissions>
              <self-uri xlink:href="advancesADV2021005941.pdf"/>
              <self-uri xlink:role="icon" xlink:href="advancesADV2021005941_thumb.jpg"/>
              <abstract abstract-type="precis">
                <title>Key Points</title>
                <p>
                  <list list-type="bullet">
                    <list-item>
                      <p>Triple antigen–bearing mRNA-electroporated autologous LC vaccines after ASCT for MM are safe and immunogenic.</p>
                    </list-item>
                  </list>
                </p>
              </abstract>
              <abstract abstract-type="graphical">
                <title>Visual Abstract</title>
                <p>
                  <fig position="float" id="absf1" fig-type="featured">
                    <graphic xlink:href="advancesADV2021005941absf1" position="float"/>
                  </fig>
                </p>
              </abstract>
              <abstract>
                <title>Abstract</title>
                <p>Posttransplant vaccination targeting residual disease is an immunotherapeutic strategy to improve antigen-specific immune responses and prolong disease-free survival after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We conducted a phase 1 vaccine trial to determine the safety, toxicity, and immunogenicity of autologous Langerhans-type dendritic cells (LCs) electroporated with CT7, MAGE-A3, and Wilms tumor 1 (WT1) messenger RNA (mRNA), after ASCT for MM. Ten patients received a priming immunization plus 2 boosters at 12, 30, and 90 days, respectively, after ASCT. Vaccines contained 9 × 10<sup>6</sup> mRNA-electroporated LCs. Ten additional patients did not receive LC vaccines but otherwise underwent identical ASCT and supportive care. At 3 months after ASCT, all patients started lenalidomide maintenance therapy. Vaccinated patients developed mild local delayed-type hypersensitivity reactions after booster vaccines, but no toxicities exceeded grade 1. At 1 and 3 months after vaccines, antigen-specific CD4 and CD8 T cells increased secretion of proinflammatory cytokines (interferon-γ, interleukin-2, and tumor necrosis factor-α) above prevaccine levels, and also upregulated the cytotoxicity marker CD107a. CD4 and CD8 T-cell repertoire analysis showed a trend for increased clonal expansion in the vaccine cohort, which was more pronounced in the CD4 compartment. Although not powered to assess clinical efficacy, treatment responses favored the vaccine arm. Triple antigen–bearing mRNA-electroporated autologous LC vaccination initiated at engraftment after ASCT, in conjunction with standard lenalidomide maintenance therapy for MM, is safe and induces antigen-specific immune reactivity. This trial was registered at <ext-link xlink:href="http://www.clinicaltrials.gov" ext-link-type="uri">www.clinicaltrials.gov</ext-link> as #NCT01995708.</p>
              </abstract>
              <counts>
                <page-count count="12"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro">
              <title>Introduction</title>
              <p>Multiple myeloma (MM), the second most common hematologic malignancy after non-Hodgkin lymphoma,<sup><xref rid="B1" ref-type="bibr">1</xref></sup> remains largely incurable despite numerous advances in treatment. High-dose chemotherapy, followed by autologous stem cell transplantation (ASCT) for MM, prolongs progression-free survival (PFS) and overall survival (OS),<sup><xref rid="B2" ref-type="bibr">2</xref></sup> but disease progression or relapse is inevitable for virtually all patients. The immune system participates in MM disease control,<sup><xref rid="B3" ref-type="bibr">3-6</xref></sup> and impaired immunity occurs with disease evolution,<sup><xref rid="B7" ref-type="bibr">7-9</xref></sup> thus providing a rationale for immune-based interventions to promote antitumor immunity and to optimize clinical outcomes.</p>
              <p>Posttransplant vaccination to control or eliminate residual disease offers an immunotherapeutic strategy to augment responses after ASCT for MM.<sup><xref rid="B10" ref-type="bibr">10,11</xref></sup> The early posttransplant period consists of a phase of immune reconstitution during which immune-suppressive factors, like regulatory T cells, are decreased in numbers, providing a favorable setting for vaccine-mediated induction of antitumor immunity.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> Also, the immunostimulatory properties of lenalidomide administered as maintenance therapy after ASCT<sup><xref rid="B12" ref-type="bibr">12</xref></sup> may enhance vaccine efficacy.<sup><xref rid="B13" ref-type="bibr">13,14</xref></sup> Therefore, the timing and context of immunization are equally important considerations as the choice of antigen and mode of antigen delivery.</p>
              <p>Dendritic cells (DCs) are critical to the onset and modulation of immune responses.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> Clinical studies have also confirmed the safety and feasibility of DC-based immunization in patients with cancer, albeit with mixed immune and clinical responses.<sup><xref rid="B16" ref-type="bibr">16</xref></sup> With rare exceptions, past studies have emphasized monocyte-derived DCs, even though CD34<sup>+</sup> hematopoietic progenitor cell (HPC)-derived Langerhans-type dendritic cells (LCs) are more potent stimulators of cytotoxic T lymphocytes (CTLs) against tumor antigens in vitro.<sup><xref rid="B17" ref-type="bibr">17-20</xref></sup> LCs, in contrast to monocyte-derived DCs, can stimulate CTLs de novo against a self-differentiation tumor antigen like Wilms tumor 1 (WT1) in vitro.<sup><xref rid="B19" ref-type="bibr">19</xref></sup> Clinical trial data have demonstrated the efficacy of vaccines that include LCs<sup><xref rid="B21" ref-type="bibr">21</xref></sup> and increased T-cell receptor (TCR) clonality after LC-based vaccination.<sup><xref rid="B22" ref-type="bibr">22</xref></sup></p>
              <p>Electroporation of DCs with messenger RNA (mRNA) encoding tumor-associated antigens is an effective method for inducing CTLs in vitro and in vivo.<sup><xref rid="B23" ref-type="bibr">23,24</xref></sup> Antigen expression after electroporation is more immunogenic than peptide pulsing<sup><xref rid="B23" ref-type="bibr">23</xref></sup> and eliminates the risk of genome integration associated with retroviral transgenes.<sup><xref rid="B25" ref-type="bibr">25,26</xref></sup> Electroporation with full-length mRNA also facilitates DCs’ processing and presentation of a broader array of peptides tailored to an individual’s own class I and II major histocompatibility complex (MHC) to responding T cells and avoids predetermining class I and II MHC restrictions. These attributes of mRNA electroporation also support more robust immune responses than achieved by single class I MHC-peptide pulsing.</p>
              <p>Relevant antigen targets for MM beyond B-cell maturation antigen include the cancer/testis antigens CT7 and MAGE-A3 and the self-differentiation antigen WT1. CT7 and MAGE-A3 are the most commonly expressed cancer/testis antigens in MM,<sup><xref rid="B27" ref-type="bibr">27-29</xref></sup> and their expression is associated with advanced-stage disease<sup><xref rid="B29" ref-type="bibr">29</xref></sup> and relapse.<sup><xref rid="B30" ref-type="bibr">30</xref></sup> WT1 expression in the bone marrow of patients with MM also correlates with greater disease burden.<sup><xref rid="B31" ref-type="bibr">31-33</xref></sup> Finally, antigen-specific immune reactivity against CT7, MAGE-A3, and WT1 has been demonstrated in MM.<sup><xref rid="B32" ref-type="bibr">32-35</xref></sup></p>
              <p>Many cancer vaccine studies have evaluated single-antigen or restricted epitope targeting. However, simultaneously targeting &gt;1 antigen without restricting to a specific MHC should enhance the extent and breadth of immune responses, leading to improved clinical outcomes. Therefore, we performed a phase 1 clinical study to determine the safety and immunogenicity of vaccination with autologous CD34<sup>+</sup> HPC-derived LCs electroporated with CT7, MAGE-A3, and WT1 mRNA for MM after ASCT. We assessed clinical outcomes and sequential postvaccination immune responses over time for each participant, as well as between individuals.</p>
            </sec>
            <sec sec-type="materials|methods">
              <title>Materials and methods</title>
              <sec>
                <title>Patients and clinical trial design</title>
                <p>This clinical trial (#NCT01995708) enrolled patients with symptomatic MM, who were within 12 months of starting induction therapy, had achieved a very good partial response (VGPR) or better by International Myeloma Working Group (IMWG) criteria after induction therapy, had not undergone prior ASCT, and were eligible for ASCT by standard institutional criteria. This phase 1 study tested safety and toxicity and also assessed immune responses stimulated by CT7, MAGE-A3, and WT1 mRNA-electroporated autologous CD34<sup>+</sup> HPC-derived LCs (supplemental Figure 1). The choice of induction therapy was not dictated by the trial. A bone marrow biopsy specimen positive for ≥1 of the 3 target antigens (CT7, MAGE-A, or WT1) by immunohistochemistry was required. The trial was conducted at Memorial Sloan Kettering Cancer Center (MSKCC), approved by the Institutional Review and Privacy Board of Memorial Hospital/MSKCC and the US Food and Drug Administration (IND 15365), and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.</p>
                <p>Twenty patients participated in the study, which consisted of 2 cohorts: a vaccine treatment arm and a control arm. Ten patients received post-ASCT vaccines at 9 × 10<sup>6</sup> LCs per dose (combination of 3 × 10<sup>6</sup> CT7 mRNA–electroporated LCs + 3 × 10<sup>6</sup> MAGE-A3 mRNA–electroporated LCs + 3 × 10<sup>6</sup> WT1 mRNA–electroporated LCs). The other 10 patients did not receive any LC vaccines but otherwise underwent identical cytoreduction, ASCT, and standard supportive care. Patients in the vaccine arm received a total of 3 vaccines: a priming immunization on day +12 post-ASCT, followed by boosters on days +30 and +90 post-ASCT. At ∼3 months after ASCT, all patients started lenalidomide maintenance therapy as per standard of care post-ASCT.</p>
                <p>For this trial, the vaccine was considered promising if &gt;5 of the 10 patients in the vaccine arm had an immunologic response. For cytokine secretion and activation epitope expression, a positive T-cell response was defined as a greater than twofold increase over prevaccine levels. The decision rule aimed to identify an agent that produced an immunologic response rate &gt;50%. The error rates of missing a promising agent or selecting a nonpromising agent were set at a maximum of 10%. The decision rule and error rates were devised using a historical database of vaccine trials performed at MSKCC.<sup><xref rid="B36" ref-type="bibr">36</xref></sup> For clonality, a positive T-cell response required an increase above baseline without respect to the degree of increase because there are no validated metrics to provide cutoffs for determining significance.</p>
              </sec>
              <sec>
                <title>Antigen screening</title>
                <p>Immunohistochemistry confirmed relevant antigen expression in formalin-fixed paraffin-embedded bone marrow biopsy specimens using monoclonal antibodies specific for CT7/MAGE-C1 (monoclonal antibody CT7-33),<sup><xref rid="B37" ref-type="bibr">37</xref></sup> MAGE-A3 (M3H67),<sup><xref rid="B27" ref-type="bibr">27</xref></sup> and WT1 (6F-H2; DAKO).<sup><xref rid="B27" ref-type="bibr">27,29,37</xref></sup> The degree of staining for each antigen on CD138<sup>+</sup> malignant plasma cells was graded as follows: negative; focal, &lt;5%; +, 5% to 25%; ++, 25% to 50%; +++, 50% to 75%; and ++++, &gt;75%. Study eligibility required a positive stain (focal to ++++) for ≥1 of the 3 antigens.</p>
              </sec>
              <sec>
                <title>Generation of human LCs for vaccines</title>
                <p>Granulocyte colony-stimulating factor–elicited CD34<sup>+</sup> HPCs (2 × 10<sup>6</sup>/kg actual body weight), collected from patients by leukapheresis at the time of peripheral blood stem cell collection for ASCT, were used to generate enriched LCs in vitro, as reported previously.<sup><xref rid="B17" ref-type="bibr">17,22</xref></sup> CD34<sup>+</sup> HPCs were cultured in serum-free X-VIVO 15 (Lonza, Basel, Switzerland), supplemented with granulocyte-macrophage colony-stimulating factor, transforming growth factor-β, and tumor necrosis factor-α (TNF-α) over 10 to 12 days in culture. FLT3 ligand and c-kit ligand were also added for the initial 5 to 6 days to enhance CD34<sup>+</sup> progenitor expansion.<sup><xref rid="B17" ref-type="bibr">17,22</xref></sup> CD34<sup>+</sup> HPC-derived LCs underwent terminal maturation in the presence of inflammatory cytokines TNF-α, interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E<sub>2</sub> for the final 24 to 48 hours.<sup><xref rid="B17" ref-type="bibr">17,22</xref></sup></p>
              </sec>
              <sec>
                <title>Production of in vitro–transcribed mRNA</title>
                <p>Plasmid expression vectors containing the gene for CT7, MAGE-A3, or WT1 under the control of a T7 (CT7 and MAGE-A3) or SP6 (WT1) promoter were used to synthesize mRNA. Plasmids were propagated in Max Efficiency DH5-α competent cells (Invitrogen) and purified using a Plasmid Maxi Kit (QIAGEN). After linearization, mRNA transcription in vitro was performed with T7/SP6 RNA polymerase (mMESSAGE mMACHINE T7/SP6 Transcription Kit; Ambion). Production of full-length capped mRNA was confirmed by agarose gel electrophoresis, followed by mRNA concentration determination by spectrophotometry.</p>
              </sec>
              <sec>
                <title>Electroporation of LCs</title>
                <p>Partially matured LCs were electroporated with CT7, MAGE-A3, or WT1 mRNA on day 12 or 13.<sup><xref rid="B38" ref-type="bibr">38</xref></sup> LCs were harvested, washed twice, and resuspended in Opti-MEM (Gibco, Invitrogen) to a final concentration of 15 × 10<sup>6</sup> cells per milliliter. Cells (200 μL) were mixed with 40 μg of mRNA and electroporated in a 2-mm gap cuvette at 700 V for 2 pulses, using a ECM 830 Square Wave Electroporation System (BTX Harvard). After electroporation, cells were returned to culture and terminally matured with inflammatory cytokines for 24 to 48 hours.<sup><xref rid="B17" ref-type="bibr">17</xref></sup></p>
              </sec>
              <sec>
                <title>Vaccine administration</title>
                <p>After terminal maturation, flow cytometry was used to determine the absolute number of CD83<sup>+</sup>CD86<sup>bright</sup>HLA-DR<sup>bright</sup>CD14<sup>neg</sup> LCs (supplemental Table 1A). Separate pools of mature LCs electroporated with CT7, MAGE-A3, or WT1 mRNA were washed and then combined in equal parts (3 × 10<sup>6</sup> mRNA-electroporated LCs per antigen based on the number of viable cells) into a single vaccine for intradermal administration at a final dose of 9 × 10<sup>6</sup> mRNA-electroporated LCs per vaccine. The initial priming vaccine used freshly generated LCs, whereas the 2 booster vaccines used viably thawed cells from the initial product, which had been cryopreserved by controlled-rate freezing and stored in liquid nitrogen until the day of administration. After meeting release criteria (supplemental Table 1B), 5 intradermal vaccines (10 × 0.1 mL) were administered at each of 2 medial limb sites adjacent to axillary or inguinofemoral nodes. There were no vaccine production failures, and all patients received the target dose for all 3 vaccines.</p>
              </sec>
              <sec>
                <title>Postvaccination monitoring and clinical outcomes</title>
                <p>Erythema and induration at injection sites were measured for delayed-type hypersensitivity reactions 48 hours after each booster vaccine. Adverse events were graded according to Common Terminology Criteria for Adverse Events, version 4.0. Dose-limiting toxicity was defined as grade 3 or higher toxicity. MM disease responses were determined according to IMWG criteria. Multiparameter flow cytometry measured minimal residual disease.<sup><xref rid="B39" ref-type="bibr">39</xref></sup> Progression-free survival (PFS) and overall survival (OS) were calculated from the time of enrollment and estimated using the Kaplan-Meier method (GraphPad Prism 8.3). The cutoff date for PFS and OS data was 1 June 2021.</p>
              </sec>
              <sec>
                <title>Postvaccination immune response assessments</title>
                <p>For patients in the vaccine arm, peripheral blood mononuclear cells (PBMCs) and bone marrow mononuclear cells (BMMCs) were collected prevaccine and then ∼1 and 3 months after the third and final vaccine. For patients in the control arm, PBMCs and BMMCs were collected at the same time points, with the exception of the BMMC collection at 1 month. Response assessments are described in the following sections.</p>
                <sec>
                  <title>Bone marrow immunophenotyping.</title>
                  <p>BMMCs were incubated with fluorochrome-conjugated antibodies and analyzed on a Cytek Aurora flow cytometer. BUV395-, BUV496-, BUV563-, BUV805-, BV421-, BV510-, BV650-, BV785-, FITC-, SparkBlue-, BB700-, BB790-, PE-, PE-CF594-, PE-Cy7-, A647-, A700-, and APC-Vio770-conjugated mouse anti-human mAbs included anti-CD3, anti-CD4, anti-CD14, anti-CD16, anti-CD25, anti-CD45RO, anti-CD68, anti–PD-1 (all from BD Biosciences), anti-CD45RA, anti-CD57, anti-CD86, anti-CD127, anti-CCR7, anti-FOXP3, anti–HLA-DR, anti–LAG-3 (all from BioLegend), anti-CD8 and anti-CD56 (Miltenyi Biotec), anti-TIM-3 (R&amp;D Systems), and SYTOX Blue/viability (Thermo Fisher). Gates were set for collection and analysis of ≥50,000 live events. Data analysis, including <italic toggle="yes">t</italic>-distributed stochastic neighbor embedding plot generation, was performed using FlowJo software (FlowJo LLC).</p>
                </sec>
                <sec>
                  <title>Antigen-specific T-cell activation and intracellular cytokine secretion.</title>
                  <p>CD4 and CD8 T-cell specificity for CT7, MAGE-A3, and WT1 was assessed with a restimulation assay.<sup><xref rid="B22" ref-type="bibr">22</xref></sup> Briefly, PBMCs were cultured with CT7, MAGE-A3, or WT1 mRNA-electroporated autologous LCs generated from the same CD34<sup>+</sup> HPCs used to make patient vaccines. Responder PBMCs were cultured with LCs, at a ratio of 10:1, along with recombinant human IL-2 (10 IU/mL; Chiron, Emeryville, CA) and IL-15 (10 ng/mL; R&amp;D Systems). After 7 days, fresh mRNA-electroporated autologous LCs were added for a second 7-day round of stimulation in the same culture conditions. Cells were then harvested for staining and analysis by flow cytometry, using established methods.<sup><xref rid="B22" ref-type="bibr">22</xref></sup> T-cell intracellular cytokine levels and activation marker expression were compared for fold changes over prevaccine baseline. Data were analyzed with FlowJo software.</p>
                </sec>
                <sec>
                  <title>TCR variable <bold>β</bold> chain sequencing.</title>
                  <p>For patients with sufficient cell yields, PBMCs from prevaccination baseline and from 1 and 3 months postvaccines were separated into CD4 and CD8 T-cell fractions using MS columns (Miltenyi Biotec) and cryopreserved for immunosequencing of the CDR3 of T-cell receptor variable β <bold>(</bold>TCR-V-β) chains using the iRepertoire platform (Huntsville, AL). Extracted genomic DNA was amplified in a bias-controlled multiplex polymerase chain reaction, followed by high-throughput sequencing. Sequences were collapsed and filtered to identify and quantify the abundance of each unique TCR-V-β CDR3.</p>
                </sec>
              </sec>
              <sec>
                <title>Statistics</title>
                <p>For immune response assessments, unpaired or paired Student <italic toggle="yes">t</italic> tests assessed differences in expression levels between time points. Statistical analyses were calculated using Prism 8 software (GraphPad), with statistical significance requiring a <italic toggle="yes">P</italic> value &lt; .05. To measure overlap of TCR clones between samples, we calculated the Morisita similarity index, defined as <inline-formula id="i1"><mml:math id="IM1" display="inline" overflow="scroll"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mstyle displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mtext>​</mml:mtext></mml:msup><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mstyle displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mtext>​</mml:mtext></mml:msup><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mstyle displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mtext>​</mml:mtext></mml:msup><mml:msubsup><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula>, where <inline-formula id="i2"><mml:math id="IM2" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="i3"><mml:math id="IM3" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> are the frequencies of clone <inline-formula id="i4"><mml:math id="IM4" display="inline" overflow="scroll"><mml:mi>i</mml:mi></mml:math></inline-formula> in both samples.</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <sec>
                <title>Patient characteristics</title>
                <p>Thirty-four patients were prescreened for the study (<xref rid="T1" ref-type="table">Table 1</xref>). Thirty-three (97%) were positive for ≥1 of the 3 required antigens (<xref rid="T2" ref-type="table">Table 2</xref>). CT7 was the most commonly expressed antigen (85.3%), followed by WT1 (58.8%), and MAGE-A3 (41.2%). The majority of patients (58.9%) expressed &gt;1 antigen, with 26.5% expressing all 3 antigens. There was 1 (2.9%) screening failure with negative expression for all 3 antigens.</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1.</label>
                  <caption>
                    <p>
Antigen expression by CD138<sup>+</sup> bone marrow plasma cells for individual patients
</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead valign="bottom">
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Patient</th>
                        <th align="center" rowspan="1" colspan="1">CT7</th>
                        <th align="center" rowspan="1" colspan="1">MAGE-A3</th>
                        <th align="center" rowspan="1" colspan="1">WT1</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" rowspan="1" colspan="1">1</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">+++</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="center" rowspan="1" colspan="1">++++</td>
                        <td align="center" rowspan="1" colspan="1">++++</td>
                        <td align="center" rowspan="1" colspan="1">+++</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">5</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">+++</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">6</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">7</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">8</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">9</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">10</td>
                        <td align="center" rowspan="1" colspan="1">+++</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">11</td>
                        <td align="center" rowspan="1" colspan="1">++++</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">12</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">13</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">14</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">15</td>
                        <td align="center" rowspan="1" colspan="1">++++</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">16</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                        <td align="center" rowspan="1" colspan="1">+++</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">17</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">18</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">19</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">20</td>
                        <td align="center" rowspan="1" colspan="1">++++</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">21</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">22</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">23</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">24</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">25</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">26</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">27</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">28</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">29</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">+++</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">30</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">31</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">32</td>
                        <td align="center" rowspan="1" colspan="1">++++</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">33</td>
                        <td align="center" rowspan="1" colspan="1">+++</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">++</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">34</td>
                        <td align="center" rowspan="1" colspan="1">++++</td>
                        <td align="center" rowspan="1" colspan="1">++++</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn1">
                      <p>Neg, negative.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap position="float" id="T2">
                  <label>Table 2.</label>
                  <caption>
                    <p>
Antigen expression patterns
</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead valign="bottom">
                      <tr>
                        <th align="center" colspan="4" rowspan="1">Antigen expression frequency</th>
                        <th align="center" colspan="4" rowspan="1">Concurrent antigen expression</th>
                      </tr>
                      <tr>
                        <th align="left" rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1">CT7</th>
                        <th align="center" rowspan="1" colspan="1">MAGE-A3</th>
                        <th align="center" rowspan="1" colspan="1">WT1</th>
                        <th align="center" rowspan="1" colspan="1">0</th>
                        <th align="center" rowspan="1" colspan="1">1</th>
                        <th align="center" rowspan="1" colspan="1">2</th>
                        <th align="center" rowspan="1" colspan="1">3</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Positive/total</td>
                        <td align="center" rowspan="1" colspan="1">29/34</td>
                        <td align="center" rowspan="1" colspan="1">14/34</td>
                        <td align="center" rowspan="1" colspan="1">20/34</td>
                        <td align="center" rowspan="1" colspan="1">1/34</td>
                        <td align="center" rowspan="1" colspan="1">13/34</td>
                        <td align="center" rowspan="1" colspan="1">11/34</td>
                        <td align="center" rowspan="1" colspan="1">9/34</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%</td>
                        <td align="center" rowspan="1" colspan="1">85.3</td>
                        <td align="center" rowspan="1" colspan="1">41.2</td>
                        <td align="center" rowspan="1" colspan="1">58.8</td>
                        <td align="center" rowspan="1" colspan="1">2.9</td>
                        <td align="center" rowspan="1" colspan="1">38.2</td>
                        <td align="center" rowspan="1" colspan="1">32.4</td>
                        <td align="center" rowspan="1" colspan="1">26.5</td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
                <p>Twenty patients enrolled on the trial and were randomized to a vaccine treatment arm (10 patients) or a control arm (10 patients). <xref rid="T3" ref-type="table">Table 3</xref> lists the demographics and MM disease characteristics. Median age was 61 years (range, 51-66) for the control arm and 59 years (range, 55-69) for the vaccine arm. All patients received lenalidomide and/or a proteasome inhibitor during induction, with the majority (90%) receiving a triplet regimen. For both arms of the study, 9 patients had achieved a VGPR and 1 patient had achieved a complete response (CR) after induction therapy and preceding ASCT. Of the 13 patients who were eligible but did not proceed on study, 7 deferred upfront ASCT, 3 had progression of disease before ASCT, and 3 did not proceed for reasons unrelated to MM disease status.</p>
                <table-wrap position="float" id="T3">
                  <label>Table 3.</label>
                  <caption>
                    <p>
Patient demographics and disease characteristics
</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead valign="bottom">
                      <tr>
                        <th align="left" rowspan="2" colspan="1">Patient</th>
                        <th align="center" rowspan="2" colspan="1">Age, y</th>
                        <th align="center" rowspan="2" colspan="1">Sex</th>
                        <th align="center" rowspan="2" colspan="1">MM subtype</th>
                        <th align="center" rowspan="2" colspan="1">R-ISS stage</th>
                        <th align="center" rowspan="2" colspan="1">Induction regimen</th>
                        <th align="center" rowspan="2" colspan="1">Dz status pre-ASCT</th>
                        <th align="center" colspan="3" rowspan="1">Antigen screening</th>
                        <th align="center" rowspan="2" colspan="1">Dz status +3 mo</th>
                        <th align="center" rowspan="2" colspan="1">Dz status +12 mo</th>
                      </tr>
                      <tr>
                        <th align="center" rowspan="1" colspan="1">CT7</th>
                        <th align="center" rowspan="1" colspan="1">MAGE-A3</th>
                        <th align="center" rowspan="1" colspan="1">WT1</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" colspan="12" rowspan="1">
                          <bold>Control arm</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 4</td>
                        <td align="center" rowspan="1" colspan="1">65</td>
                        <td align="center" rowspan="1" colspan="1">F</td>
                        <td align="center" rowspan="1" colspan="1">IgGλ</td>
                        <td align="center" rowspan="1" colspan="1">III− t(4;14)</td>
                        <td align="center" rowspan="1" colspan="1">RVd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">+1</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">Relapse</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 6</td>
                        <td align="center" rowspan="1" colspan="1">66</td>
                        <td align="center" rowspan="1" colspan="1">F</td>
                        <td align="center" rowspan="1" colspan="1">IgGκ</td>
                        <td align="center" rowspan="1" colspan="1">II</td>
                        <td align="center" rowspan="1" colspan="1">RVd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">+3</td>
                        <td align="center" rowspan="1" colspan="1">+2</td>
                        <td align="center" rowspan="1" colspan="1">+2</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 8</td>
                        <td align="center" rowspan="1" colspan="1">51</td>
                        <td align="center" rowspan="1" colspan="1">M</td>
                        <td align="center" rowspan="1" colspan="1">IgAλ</td>
                        <td align="center" rowspan="1" colspan="1">III</td>
                        <td align="center" rowspan="1" colspan="1">CyBorD</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">CR (+)</td>
                        <td align="center" rowspan="1" colspan="1">Relapse</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 10</td>
                        <td align="center" rowspan="1" colspan="1">61</td>
                        <td align="center" rowspan="1" colspan="1">F</td>
                        <td align="center" rowspan="1" colspan="1">IgAκ</td>
                        <td align="center" rowspan="1" colspan="1">I</td>
                        <td align="center" rowspan="1" colspan="1">RVd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">+1</td>
                        <td align="center" rowspan="1" colspan="1">CR (−)</td>
                        <td align="center" rowspan="1" colspan="1">CR (+)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 12</td>
                        <td align="center" rowspan="1" colspan="1">65</td>
                        <td align="center" rowspan="1" colspan="1">M</td>
                        <td align="center" rowspan="1" colspan="1">κFLC</td>
                        <td align="center" rowspan="1" colspan="1">II</td>
                        <td align="center" rowspan="1" colspan="1">CyBorD</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">+2</td>
                        <td align="center" rowspan="1" colspan="1">+1</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">CR (+)</td>
                        <td align="center" rowspan="1" colspan="1">CR (−)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 14</td>
                        <td align="center" rowspan="1" colspan="1">52</td>
                        <td align="center" rowspan="1" colspan="1">F</td>
                        <td align="center" rowspan="1" colspan="1">IgAλ</td>
                        <td align="center" rowspan="1" colspan="1">III− t(14;16)</td>
                        <td align="center" rowspan="1" colspan="1">KRd</td>
                        <td align="center" rowspan="1" colspan="1">CR (−)</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Relapse</td>
                        <td align="center" rowspan="1" colspan="1">Relapse</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 16</td>
                        <td align="center" rowspan="1" colspan="1">56</td>
                        <td align="center" rowspan="1" colspan="1">M</td>
                        <td align="center" rowspan="1" colspan="1">IgGκ</td>
                        <td align="center" rowspan="1" colspan="1">I</td>
                        <td align="center" rowspan="1" colspan="1">KRd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">+2</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 17</td>
                        <td align="center" rowspan="1" colspan="1">59</td>
                        <td align="center" rowspan="1" colspan="1">M</td>
                        <td align="center" rowspan="1" colspan="1">IgGκ</td>
                        <td align="center" rowspan="1" colspan="1">II</td>
                        <td align="center" rowspan="1" colspan="1">KRd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">CR (+)</td>
                        <td align="center" rowspan="1" colspan="1">CR (+)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 19</td>
                        <td align="center" rowspan="1" colspan="1">62</td>
                        <td align="center" rowspan="1" colspan="1">F</td>
                        <td align="center" rowspan="1" colspan="1">IgAλ</td>
                        <td align="center" rowspan="1" colspan="1">III− del17</td>
                        <td align="center" rowspan="1" colspan="1">RVd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">+4</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">CR (+)</td>
                        <td align="center" rowspan="1" colspan="1">CR (−)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 20</td>
                        <td align="center" rowspan="1" colspan="1">61</td>
                        <td align="center" rowspan="1" colspan="1">F</td>
                        <td align="center" rowspan="1" colspan="1">IgGκ</td>
                        <td align="center" rowspan="1" colspan="1">II</td>
                        <td align="center" rowspan="1" colspan="1">RVd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">+4</td>
                        <td align="center" rowspan="1" colspan="1">+4</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">Relapse</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">Median, 61 Range, 51-66</td>
                        <td align="center" rowspan="1" colspan="1">M = 4 F = 6</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">I = 2 II = 4 III = 4 III = 4</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">VGPR = 9 CR = 1</td>
                        <td align="center" rowspan="1" colspan="1">8</td>
                        <td align="center" rowspan="1" colspan="1">3</td>
                        <td align="center" rowspan="1" colspan="1">3</td>
                        <td align="center" rowspan="1" colspan="1">VGPR = 4 CR (+) = 3 CR (−) = 2 Relapse = 1</td>
                        <td align="center" rowspan="1" colspan="1">CR (+) = 2 CR (−) = 2 VGPR = 2 Relapse = 4</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="12" rowspan="1">
                          <bold>Vaccine arm</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 1</td>
                        <td align="center" rowspan="1" colspan="1">60</td>
                        <td align="center" rowspan="1" colspan="1">M</td>
                        <td align="center" rowspan="1" colspan="1">κFLC</td>
                        <td align="center" rowspan="1" colspan="1">I</td>
                        <td align="center" rowspan="1" colspan="1">Rd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">+1</td>
                        <td align="center" rowspan="1" colspan="1">CR (−)</td>
                        <td align="center" rowspan="1" colspan="1">CR (−)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 2</td>
                        <td align="center" rowspan="1" colspan="1">55</td>
                        <td align="center" rowspan="1" colspan="1">F</td>
                        <td align="center" rowspan="1" colspan="1">IgGκ</td>
                        <td align="center" rowspan="1" colspan="1">I</td>
                        <td align="center" rowspan="1" colspan="1">Vd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">+4</td>
                        <td align="center" rowspan="1" colspan="1">+4</td>
                        <td align="center" rowspan="1" colspan="1">+3</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">Relapse</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 3</td>
                        <td align="center" rowspan="1" colspan="1">58</td>
                        <td align="center" rowspan="1" colspan="1">M</td>
                        <td align="center" rowspan="1" colspan="1">IgAλ</td>
                        <td align="center" rowspan="1" colspan="1">II</td>
                        <td align="center" rowspan="1" colspan="1">RVd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">+3</td>
                        <td align="center" rowspan="1" colspan="1">CR (−)</td>
                        <td align="center" rowspan="1" colspan="1">CR (−)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 5</td>
                        <td align="center" rowspan="1" colspan="1">59</td>
                        <td align="center" rowspan="1" colspan="1">M</td>
                        <td align="center" rowspan="1" colspan="1">IgGκ</td>
                        <td align="center" rowspan="1" colspan="1">I</td>
                        <td align="center" rowspan="1" colspan="1">RVd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">+2</td>
                        <td align="center" rowspan="1" colspan="1">+1</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">CR (−)</td>
                        <td align="center" rowspan="1" colspan="1">CR (−)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 7</td>
                        <td align="center" rowspan="1" colspan="1">55</td>
                        <td align="center" rowspan="1" colspan="1">M</td>
                        <td align="center" rowspan="1" colspan="1">κFLC</td>
                        <td align="center" rowspan="1" colspan="1">II− del17</td>
                        <td align="center" rowspan="1" colspan="1">RVd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">+2</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">+1</td>
                        <td align="center" rowspan="1" colspan="1">CR (+)</td>
                        <td align="center" rowspan="1" colspan="1">CR (+)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 9</td>
                        <td align="center" rowspan="1" colspan="1">64</td>
                        <td align="center" rowspan="1" colspan="1">M</td>
                        <td align="center" rowspan="1" colspan="1">IgGλ</td>
                        <td align="center" rowspan="1" colspan="1">I</td>
                        <td align="center" rowspan="1" colspan="1">RVd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">+4</td>
                        <td align="center" rowspan="1" colspan="1">+2</td>
                        <td align="center" rowspan="1" colspan="1">+2</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">CR (−)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 11</td>
                        <td align="center" rowspan="1" colspan="1">59</td>
                        <td align="center" rowspan="1" colspan="1">M</td>
                        <td align="center" rowspan="1" colspan="1">IgDλ</td>
                        <td align="center" rowspan="1" colspan="1">III− t(4;14)</td>
                        <td align="center" rowspan="1" colspan="1">RVd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">CR (+)</td>
                        <td align="center" rowspan="1" colspan="1">CR (+)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 13</td>
                        <td align="center" rowspan="1" colspan="1">55</td>
                        <td align="center" rowspan="1" colspan="1">F</td>
                        <td align="center" rowspan="1" colspan="1">IgAκ</td>
                        <td align="center" rowspan="1" colspan="1">II</td>
                        <td align="center" rowspan="1" colspan="1">RVd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">+1</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">CR (−)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 15</td>
                        <td align="center" rowspan="1" colspan="1">61</td>
                        <td align="center" rowspan="1" colspan="1">M</td>
                        <td align="center" rowspan="1" colspan="1">κFLC</td>
                        <td align="center" rowspan="1" colspan="1">I</td>
                        <td align="center" rowspan="1" colspan="1">KRd</td>
                        <td align="center" rowspan="1" colspan="1">CR (+)</td>
                        <td align="center" rowspan="1" colspan="1">+2</td>
                        <td align="center" rowspan="1" colspan="1">Neg</td>
                        <td align="center" rowspan="1" colspan="1">+1</td>
                        <td align="center" rowspan="1" colspan="1">CR (+)</td>
                        <td align="center" rowspan="1" colspan="1">CR (+)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 18</td>
                        <td align="center" rowspan="1" colspan="1">69</td>
                        <td align="center" rowspan="1" colspan="1">M</td>
                        <td align="center" rowspan="1" colspan="1">IgGλ</td>
                        <td align="center" rowspan="1" colspan="1">II</td>
                        <td align="center" rowspan="1" colspan="1">RVd</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">Focal</td>
                        <td align="center" rowspan="1" colspan="1">+3</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                        <td align="center" rowspan="1" colspan="1">VGPR</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">Median, 59 Range, 55-69</td>
                        <td align="center" rowspan="1" colspan="1">M = 8 F = 2</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">I = 5 II = 4 III = 1</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">VGPR = 9 CR = 1</td>
                        <td align="center" rowspan="1" colspan="1">8</td>
                        <td align="center" rowspan="1" colspan="1">5</td>
                        <td align="center" rowspan="1" colspan="1">8</td>
                        <td align="center" rowspan="1" colspan="1">VGPR = 4 CR (+) = 3 CR (−) = 3</td>
                        <td align="center" rowspan="1" colspan="1">CR (+) = 3 CR (−) = 5 VGPR = 1 Relapse = 1</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>CyBorD, cyclophosphamide/bortezomib/dexamethasone; Dz, disease; F, female; KRd, carfilzomib (KYPROLIS)/lenalidomide (REVLIMID)/dexamethasone; M, male; Neg, negative; Rd, lenalidomide (REVLIMID)/dexamethasone; R-ISS, Revised International Staging System; RVd, lenalidomide (REVLIMID)/bortezomib (VELCADE)/dexamethasone; Vd, bortezomib (VELCADE)/dexamethasone; (+), MRD positive, (−), MRD negative.</p>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec>
                <title>Clinical outcomes</title>
                <p>All patients in the vaccine cohort completed the 3 scheduled vaccines, which were tolerated well. Treatment-related adverse events were no greater than grade 1 and self-limited, with the most common being erythema, induration, and mild pruritus at the injection sites, most pronounced after the third vaccine (supplemental Figure 2).</p>
                <p>Although not designed to assess clinical efficacy, clinical responses are presented in <xref rid="T3" ref-type="table">Table 3</xref> and <xref rid="F1" ref-type="fig">Figure 1</xref>, acknowledging that a higher fraction of patients with Revised International Staging System stage III disease in the control arm and the small sample size limit interpretation. Restaging at 3 months post-ASCT for patients in the control arm found 2 patients with minimal residual disease (MRD)-negative CR, 3 patients with MRD-positive CR, 4 patients with VGPR, and 1 patient with relapsed disease. Restaging at 3 months post-ASCT for patients in the vaccine arm identified 3 patients with MRD-negative CR, 3 patients with MRD-positive CR, and 4 patients with VGPR. Restaging at 12 months post-ASCT for patients in the control arm showed 2 patients with MRD-negative CR, 2 patients with MRD-positive CR, 2 patients with VGPR, and 4 patients with relapsed disease. Restaging at 12 months post-ASCT for patients in the vaccine arm showed 5 patients with MRD-negative CR, 3 patients with MRD-positive CR, 1 patient with VGPR, and 1 patient with relapsed disease.</p>
                <fig position="float" id="F1">
                  <label>Figure 1.</label>
                  <caption>
                    <p><bold>Clinical responses after ASCT and mRNA-electroporated LC vaccines.</bold> (A) Depth of response pre-ASCT and at days +90 (d90) and +365 (d365) after ASCT. Relapse is also indicated. PFS and OS for patients in the control arm (B) and the vaccine arm (C). D, deceased; R, relapse.</p>
                  </caption>
                  <graphic xlink:href="advancesADV2021005941f1" position="float"/>
                </fig>
                <p>For all patients in the study, median follow-up was 59.5 months. For patients in the unvaccinated control arm, 4 remained progression free, with a median PFS of 31 months (range, 3-63). Two patients died, both from MM disease progression, with a median OS of 46 months (range, 12-79). For patients in the vaccine arm, 6 remained progression free, with a median PFS of 54 months (range, 12-85). All patients are alive, with a median OS of 71 months (range, 45-85). There was no clear association between PFS and the extent of CT7, MAGE-A3, or WT1 expression at diagnosis (data not shown).</p>
              </sec>
              <sec>
                <title>Posttreatment immune profiling of the bone marrow microenvironment</title>
                <p>Immunophenotyping of the bone marrow microenvironment after vaccination, compared with prevaccine levels and summarized in <xref rid="F2" ref-type="fig">Figure 2</xref>, showed expansion of CD4 and CD8 effector memory T cells (CCR7<sup>neg</sup>CD45RA<sup>neg</sup>), suppression of CD4 and CD8 naive T cells (CCR7<sup>+</sup>CD45RO<sup>neg</sup>), and upregulation of T cells expressing the immune checkpoint receptor PD-1. For vaccinated patients, CD4 and CD8 effector memory T cells peaked at 1 month (<xref rid="F2" ref-type="fig">Figure 2B-C</xref>), along with expression of PD-1 (<xref rid="F2" ref-type="fig">Figure 2B</xref>) but not LAG-3 or TIM-3 (data not shown). Control patients showed similar patterns at 3 months (<xref rid="F2" ref-type="fig">Figure 2B-C</xref>); 1-month bone marrow samples were not obtained for this cohort. The relative proportions of natural killer cells, regulatory T cells, exhausted/senescent T cells, and myeloid-derived suppressor cells were similar between the 2 cohorts (data not shown). In aggregate, these findings show an inflammatory effector-skewed environment in the early posttransplant period without substantial phenotypic differences between the vaccine and nonvaccine arms.</p>
                <fig position="float" id="F2">
                  <label>Figure 2.</label>
                  <caption>
                    <p><bold>Bone marrow immunophenotyping after ASCT and mRNA-electroporated LC vaccines.</bold> BMMCs were analyzed by flow cytometry to profile the lymphocyte composition postvaccination in comparison with baseline (prevaccine) and an unvaccinated control cohort. (A) <italic toggle="yes">t</italic>-Distributed stochastic neighbor embedding plots at 3 months after vaccination showing CD4 and CD8 T cells (far left plot), CD4 and CD8 effector memory cells (T<sub>EM</sub>; CCR7<sup>neg</sup>CD45RA<sup>neg</sup>) (middle left plot), CD4 and CD8 naive cells (T<sub>N</sub>; CCR7<sup>+</sup>CD45RO<sup>neg</sup>) (middle right plot), and PD-1–expressing CD4 and CD8 cells (far right plot). CD4 (B) and CD8 (C) effector memory, naive, and PD-1–expressing cells at 1 and 3 months after vaccines. Pooled data (mean ± standard deviation) are shown for patients in the control (red circles) and vaccine (blue squares) arms. ns, not significant; Pre, prevaccine.</p>
                  </caption>
                  <graphic xlink:href="advancesADV2021005941f2" position="float"/>
                </fig>
              </sec>
              <sec>
                <title>Antigen-specific immune reactivity</title>
                <p>To assess antigen-specific reactivity after vaccination, PBMCs obtained at 1 and 3 months after completion of vaccines were restimulated in vitro with freshly generated autologous LCs electroporated with CT7, MAGE-A3, and WT1 mRNA. Samples collected at parallel time points from unvaccinated patients served as controls. CD4 T-cell secretion of interferon-γ (IFN-γ), IL-2, and TNF-α increased 5.54-, 4.49-, and 3.46-fold, respectively, at 1 month postvaccination, and remained elevated (5.69-, 5.32-, and 2.54-fold, respectively) at 3 months postvaccination (<xref rid="F3" ref-type="fig">Figure 3A</xref>). CD4 T cells also upregulated Mip-1β, a marker of activation, 2.62- and 2.46-fold and CD107a, a marker of degranulation, 2.76- and 4.24-fold, at the 1 and 3-month time points, respectively (<xref rid="F3" ref-type="fig">Figure 3A</xref>). Similar to CD4 T-cell responses, antigen-specific CD8 T-cell secretion of IFN-γ, IL-2, and TNF-α increased 5.06-, 4.6-, and 4.68-fold, respectively, at 1 month postvaccination and increased 6.2-, 5.52-, and 2.8-fold, respectively, at 3 months postvaccination (<xref rid="F3" ref-type="fig">Figure 3B</xref>). Upregulation of Mip-1β and CD107a by CD8 T cells was not as pronounced as by CD4 T cells (<xref rid="F3" ref-type="fig">Figure 3B</xref>). Limited cell yields precluded assessment of antigen-specific CTL activity in killing assays. Restimulation assays using BMMCs corroborated the PBMC findings, with increased cytokine secretion and activation marker expression in the CD4 and CD8 T-cell compartments at 3 months postvaccination (<xref rid="F3" ref-type="fig">Figure 3C-D</xref>).</p>
                <fig position="float" id="F3">
                  <label>Figure 3.</label>
                  <caption>
                    <p><bold>LC vaccines after ASCT stimulate antigen-specific CD4 and CD8 T-cell cytokine secretion and activation epitope expression.</bold> Postvaccination recall responses to CT7, MAGE-A3, and WT1 mRNA-electroporated LCs were measured as the fold change increase above prevaccine baseline using PBMCs at 1 and 3 months after vaccines (A-B) and BMMCs at 3 months after vaccines (C-D). Fold change in CD4 (A,C) and CD8 (B,D) T-cell proinflammatory cytokine (IFN-γ, IL-2, and TNF-α) secretion and activation epitope (CD107a and Mip-1β) expression. Pooled data (mean ± standard deviation) are shown for patients from the control (red circles) and vaccine (blue squares) arms. ns, not significant.</p>
                  </caption>
                  <graphic xlink:href="advancesADV2021005941f3" position="float"/>
                </fig>
              </sec>
              <sec>
                <title>CD4 and CD8 T-cell clonality after vaccination with mRNA-electroporated LCs</title>
                <p>CD4 and CD8 T cells isolated from PBMCs collected after vaccination underwent next-generation deep sequencing of the TCR-V-β CDR3, with samples from unvaccinated patients providing controls. Pre- to postvaccination TCR repertoire composition varied over time for all patients and was generally similar for the vaccine and control cohorts (<xref rid="F4" ref-type="fig">Figure 4A</xref>), indicating that the post-ASCT TCR repertoire is shaped by factors intrinsic to immune reconstitution after transplant. For both cohorts, the CD4 compartment possessed a higher fraction of low-frequency clones, whereas the CD8 compartment maintained a greater abundance of dominant high-frequency clones (<xref rid="F4" ref-type="fig">Figure 4A</xref>), which has been described in the setting of ASCT for multiple sclerosis.<sup><xref rid="B40" ref-type="bibr">40</xref></sup> Longitudinal assessment of shared clones from day 12 to day 120 after ASCT, using the Morisita similarity index, revealed consistency between samples over time from the same individuals with infrequent overlap of clones between individuals or between groups (<xref rid="F4" ref-type="fig">Figure 4B</xref>). TCR clonal expansion after ASCT, identified by mean log fold change from baseline at day 12, with emphasis on consistently expanded clones to minimize sample noise, showed increases that were most pronounced in the CD4 compartment of the vaccine cohort (<xref rid="F4" ref-type="fig">Figure 4C</xref>). However, these did not reach statistical significance because of the limited sample size.</p>
                <fig position="float" id="F4">
                  <label>Figure 4.</label>
                  <caption>
                    <p><bold>T-cell clonality after ASCT and vaccination with mRNA-electroporated LCs.</bold> Next-generation deep sequencing of the TCR-V-β CDR3 was performed on CD4 and CD8 T cells isolated from PBMCs obtained at days 30, 90, and 120 after ASCT and compared with prevaccine levels (day 12). (A) Stacked bar plots of CD4 and CD8 T-cell repertoire composition from 6 representative patients (3 from vaccine arm, 3 from control arm). Each color represents a unique clone, with the higher-percentage clones at the top and lower-percentage clones underneath (low-frequency clones blend together in black). (B) Heat maps of interpatient overlap of CD4 and CD8 T-cell clones calculated using the Morisita similarity index (dark yellow = similar; dark green = dissimilar). V1-V9 along the x- and y-axes represent vaccinated patients. C1-C9 along the x- and y-axes represent control patients. (C) Violin plots representing the mean log fold change in CD4 and CD8 T-cell expansion. Each color represents an individual patient. The red dashed line represents the mean log fold change value in each group. D12, day 12; D30, day 30; D90, day +90; D120, day 120.</p>
                  </caption>
                  <graphic xlink:href="advancesADV2021005941f4" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>Vaccination with triple antigen–bearing mRNA-electroporated autologous LCs initiated at the onset of engraftment after ASCT for MM, followed by lenalidomide maintenance therapy, is safe and feasible. Vaccines are tolerated well, with only mild delayed-type hypersensitivity reactions at injection sites after booster vaccines. Postvaccine immune assessments detected antigen-specific CD4 and CD8 T-cell activation and proinflammatory cytokine secretion, as well as a trend toward greater T-cell clonal expansion. Although not powered to assess clinical efficacy, treatment responses favored the vaccine arm.</p>
              <p>The vaccine platform of this study exploited the superior potency of LCs over other DC subtypes,<sup><xref rid="B17" ref-type="bibr">17-20</xref></sup> combined with electroporation of full-length mRNA<sup><xref rid="B23" ref-type="bibr">23,24,38</xref></sup> encoding 3 tumor antigens, to promote a broad T-cell response during immune reconstitution in the first 100 days after ASCT.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> This was coupled with the immune adjuvant activity of posttransplant lenalidomide maintenance therapy.<sup><xref rid="B13" ref-type="bibr">13,14</xref></sup> Comprehensive immunophenotyping of the bone marrow microenvironment showed generalized activation with increased effector memory cell populations in the setting of immune reconstitution post-ASCT. Vaccination-induced antigen-specific activation of CD4 and CD8 T cells was sustained at 3 months after the third and final dose of mRNA-electroporated LCs.</p>
              <p>Greater T-cell diversity after immune-based interventions correlates with clinical benefit,<sup><xref rid="B41" ref-type="bibr">41,42</xref></sup> but altered clonality is an incomplete gauge of antitumor capacity. This is particularly true of the TCR repertoire after ASCT. Specifically, to our knowledge, this study is the first with TCR analysis in the setting of transplant to include a control cohort demonstrating natural fluctuations in TCR frequency during immune reconstitution after transplant alone. Therefore, this provides a true reference baseline, without which interpretations of changes in the TCR repertoire of the vaccine cohort would have been skewed much more in favor of a potential vaccine effect. Although there were no significant differences in the overall pattern of T-cell reconstitution or TCR repertoire diversity between the vaccine and control groups in this study, TCR clonotype expansion from the prevaccine time point was detected in the CD4 compartment and, to a lesser degree, in the CD8 compartment of vaccinated patients, suggestive of a treatment effect but limited by the small sample size. The nuanced nature of vaccine-mediated changes in the immune repertoire, as well as the challenges of detecting subtle, yet immunologically relevant, changes in TCR clonal composition, highlight the need for higher-resolution assays to map TCRs accurately to their antigen targets and to identify protective TCR clones.</p>
              <p>Having generated functionally competent LCs ex vivo from patients with MM for this trial, we nevertheless acknowledge the resource limitations for collecting and processing granulocyte colony-stimulating factor–mobilized CD34<sup>+</sup> HPCs as LC precursors, as well as the time, cost, and labor of manufacturing vaccines in vitro. These issues restrict the broad clinical application of such LC-based vaccines generated in vitro. Studies to circumvent the production process ex vivo by activating LCs or other DC subsets directly in vivo are ongoing. Despite concerns that the dysfunctional activity of endogenous DCs in MM<sup><xref rid="B43" ref-type="bibr">43-45</xref></sup> may compromise direct targeting of DCs in vivo, DCs from patients with MM can induce MM-specific T cells ex vivo.<sup><xref rid="B4" ref-type="bibr">4,46</xref></sup> Therefore, this implicates factors within the bone marrow tumor microenvironment, like IL-6,<sup><xref rid="B43" ref-type="bibr">43</xref></sup> that may regulate DC priming of antitumor immunity.</p>
              <p>Immune-suppressive cells, including myeloid-derived suppressor cells,<sup><xref rid="B47" ref-type="bibr">47</xref></sup> regulatory T cells,<sup><xref rid="B48" ref-type="bibr">48</xref></sup> and tumor-associated macrophages,<sup><xref rid="B49" ref-type="bibr">49</xref></sup> populate the MM tumor microenvironment. In addition, immune dysfunction, including T-cell exhaustion and/or senescence, correlates with inferior outcomes after ASCT,<sup><xref rid="B9" ref-type="bibr">9,50,51</xref></sup> characterizes multiply relapsed disease,<sup><xref rid="B52" ref-type="bibr">52</xref></sup> and is potentially reversible with immune checkpoint blockade.<sup><xref rid="B9" ref-type="bibr">9,50,52</xref></sup> Therefore, vaccine-extrinsic factors, including elements within the tumor microenvironment and the impaired functional capacity of responding T cells, can subvert optimal T-cell activation,<sup><xref rid="B52" ref-type="bibr">52</xref></sup> underscoring the complexities of eliciting effective immune responses in the setting of malignancy.</p>
              <p>Emerging immune-based therapies for MM include antibody-drug conjugates, bispecific antibody constructs, and chimeric antigen receptor T cells, which have shown promising activity in advanced MM.<sup><xref rid="B53" ref-type="bibr">53</xref></sup> Durable responses to these treatments are infrequent, but combination strategies with vaccines to prime anti-MM immunity offer an approach to boost responses. For example, vaccination prior to bispecific antibody constructs may augment therapeutic potency by creating pools of antigen-experienced T cells. Vaccines can also promote the expansion and efficacy of chimeric antigen receptor T cells.<sup><xref rid="B54" ref-type="bibr">54,55</xref></sup></p>
              <p>This study highlights the feasibility of immunizing patients with MM with mRNA-electroporated LCs after ASCT to induce measurable cellular immune responses against multiple antigens simultaneously. Identification and optimization of rational combinations, timing, and sequencing of DC-based vaccines, including targeting of endogenous DC subtypes, along with other immune-directed interventions, will most likely exert the greatest benefit on improved and durable clinical responses.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <p>The full-text version of this article contains a data supplement.</p>
              <supplementary-material id="SD1" position="float" content-type="local-data">
                <media xlink:href="advancesADV2021005941-suppl1.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="SD2" position="float" content-type="local-data">
                <media xlink:href="advancesADV2021005941-suppl2.zip">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>The authors thank the patients for participating in the clinical trial. They gratefully acknowledge the contributions of members of the Laboratory of Cellular Immunobiology to the development of this work. They also thank the nurses, advanced practice providers, research staff, and physicians of the Myeloma and Adult Bone Marrow Transplant Services, the Blood Bank Donor Room, and the Cell Therapy Laboratory.</p>
              <p>This work was supported by William H. Goodwin and Alice Goodwin and the Commonwealth Foundation for Cancer Research, the Experimental Therapeutics Center of MSKCC (D.J.C.), the Society of Memorial Sloan Kettering (D.J.C.), the Khalily Myeloma Research Fund (D.J.C.), the Guthart Myeloma Research Fund (D.J.C.), the Sawaris Myeloma Research Fund (D.J.C.), American Society of Clinical Oncology Young Investigator Award (S.D.), and Swim Across America, Long Island Sound Chapter. This work was also funded through National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748, P01 CA023766, and T32 CA00915.</p>
            </ack>
            <sec>
              <title>Authorship</title>
              <p>Contribution: D.J.C. designed and supervised the study, collected data, analyzed and interpreted data, and wrote the manuscript; S.S. and M.R. performed experiments and edited the manuscript; S.D. interpreted data and edited the manuscript; Y.E. analyzed and interpreted data and edited the manuscript; K.P. performed experiments, analyzed and interpreted data, and edited the manuscript; and J.W.Y. designed and supervised the study, interpreted data, and edited the manuscript.</p>
              <p>Conflict-of-interest disclosure: The authors declare no competing financial interests.</p>
              <p>The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
              <p>Correspondence: David J. Chung, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; e-mail: <email xlink:href="mailto:chungd1@mskcc.org">chungd1@mskcc.org</email>.</p>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siegel</surname><given-names>RL</given-names></string-name>, <string-name><surname>Miller</surname><given-names>KD</given-names></string-name>, <string-name><surname>Jemal</surname><given-names>A</given-names></string-name></person-group>. <article-title>Cancer statistics, 2020</article-title>. <source>CA Cancer J Clin.</source><year>2020</year>;<volume>70</volume>(<issue>1</issue>):<fpage>7</fpage>-<lpage>30</lpage>.<pub-id pub-id-type="pmid">31912902</pub-id></mixed-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mikhael</surname><given-names>J</given-names></string-name>, <string-name><surname>Ismaila</surname><given-names>N</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>MC</given-names></string-name>, <etal/></person-group>. <article-title>Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline</article-title> [published correction appears in <italic toggle="yes">J Clin Oncol</italic>. 2020;38(21):2469]. <source>J Clin Oncol.</source>
<year>2019</year>;<volume>37</volume>(<issue>14</issue>):<fpage>1228</fpage>-<lpage>1263</lpage>.<pub-id pub-id-type="pmid">30932732</pub-id></mixed-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pellat-Deceunynck</surname><given-names>C</given-names></string-name>, <string-name><surname>Jego</surname><given-names>G</given-names></string-name>, <string-name><surname>Harousseau</surname><given-names>JL</given-names></string-name>, <string-name><surname>Vié</surname><given-names>H</given-names></string-name>, <string-name><surname>Bataille</surname><given-names>R</given-names></string-name></person-group>. <article-title>Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells</article-title>. <source>Clin Cancer Res.</source><year>1999</year>;<volume>5</volume>(<issue>3</issue>):<fpage>705</fpage>-<lpage>709</lpage>.<pub-id pub-id-type="pmid">10100725</pub-id></mixed-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dhodapkar</surname><given-names>MV</given-names></string-name>, <string-name><surname>Krasovsky</surname><given-names>J</given-names></string-name>, <string-name><surname>Olson</surname><given-names>K</given-names></string-name></person-group>. <article-title>T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells</article-title>. <source>Proc Natl Acad Sci USA.</source><year>2002</year>;<volume>99</volume>(<issue>20</issue>):<fpage>13009</fpage>-<lpage>13013</lpage>.<pub-id pub-id-type="pmid">12235374</pub-id></mixed-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Noonan</surname><given-names>K</given-names></string-name>, <string-name><surname>Matsui</surname><given-names>W</given-names></string-name>, <string-name><surname>Serafini</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors</article-title>. <source>Cancer Res.</source><year>2005</year>;<volume>65</volume>(<issue>5</issue>):<fpage>2026</fpage>-<lpage>2034</lpage>.<pub-id pub-id-type="pmid">15753403</pub-id></mixed-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goodyear</surname><given-names>O</given-names></string-name>, <string-name><surname>Piper</surname><given-names>K</given-names></string-name>, <string-name><surname>Khan</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>CD8<sup>+</sup> T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden</article-title>. <source>Blood.</source><year>2005</year>;<volume>106</volume>(<issue>13</issue>):<fpage>4217</fpage>-<lpage>4224</lpage>.<pub-id pub-id-type="pmid">16144804</pub-id></mixed-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dhodapkar</surname><given-names>MV</given-names></string-name>, <string-name><surname>Krasovsky</surname><given-names>J</given-names></string-name>, <string-name><surname>Osman</surname><given-names>K</given-names></string-name>, <string-name><surname>Geller</surname><given-names>MD</given-names></string-name></person-group>. <article-title>Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy</article-title>. <source>J Exp Med.</source><year>2003</year>;<volume>198</volume>(<issue>11</issue>):<fpage>1753</fpage>-<lpage>1757</lpage>.<pub-id pub-id-type="pmid">14638846</pub-id></mixed-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spisek</surname><given-names>R</given-names></string-name>, <string-name><surname>Kukreja</surname><given-names>A</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L-C</given-names></string-name>, <etal/></person-group>. <article-title>Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy</article-title>. <source>J Exp Med.</source><year>2007</year>;<volume>204</volume>(<issue>4</issue>):<fpage>831</fpage>-<lpage>840</lpage>.<pub-id pub-id-type="pmid">17389240</pub-id></mixed-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chung</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Pronschinske</surname><given-names>KB</given-names></string-name>, <string-name><surname>Shyer</surname><given-names>JA</given-names></string-name>, <etal/></person-group>. <article-title>T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy</article-title>. <source>Cancer Immunol Res.</source><year>2016</year>;<volume>4</volume>(<issue>1</issue>):<fpage>61</fpage>-<lpage>71</lpage>.<pub-id pub-id-type="pmid">26464015</pub-id></mixed-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rosenblatt</surname><given-names>J</given-names></string-name>, <string-name><surname>Avivi</surname><given-names>I</given-names></string-name>, <string-name><surname>Vasir</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients</article-title>. <source>Clin Cancer Res.</source><year>2013</year>;<volume>19</volume>(<issue>13</issue>):<fpage>3640</fpage>-<lpage>3648</lpage>.<pub-id pub-id-type="pmid">23685836</pub-id></mixed-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cohen</surname><given-names>AD</given-names></string-name>, <string-name><surname>Lendvai</surname><given-names>N</given-names></string-name>, <string-name><surname>Nataraj</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Autologous lymphocyte infusion supports tumor antigen vaccine-induced immunity in autologous stem cell transplant for multiple myeloma</article-title>. <source>Cancer Immunol Res.</source><year>2019</year>;<volume>7</volume>(<issue>4</issue>):<fpage>658</fpage>-<lpage>669</lpage>.<pub-id pub-id-type="pmid">30745365</pub-id></mixed-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McCarthy</surname><given-names>PL</given-names></string-name>, <string-name><surname>Holstein</surname><given-names>SA</given-names></string-name>, <string-name><surname>Petrucci</surname><given-names>MT</given-names></string-name>, <etal/></person-group>. <article-title>Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis</article-title>. <source>J Clin Oncol.</source><year>2017</year>;<volume>35</volume>(<issue>29</issue>):<fpage>3279</fpage>-<lpage>3289</lpage>.<pub-id pub-id-type="pmid">28742454</pub-id></mixed-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Görgün</surname><given-names>G</given-names></string-name>, <string-name><surname>Calabrese</surname><given-names>E</given-names></string-name>, <string-name><surname>Soydan</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma</article-title>. <source>Blood.</source><year>2010</year>;<volume>116</volume>(<issue>17</issue>):<fpage>3227</fpage>-<lpage>3237</lpage>.<pub-id pub-id-type="pmid">20651070</pub-id></mixed-citation>
              </ref>
              <ref id="B14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luptakova</surname><given-names>K</given-names></string-name>, <string-name><surname>Rosenblatt</surname><given-names>J</given-names></string-name>, <string-name><surname>Glotzbecker</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Lenalidomide enhances anti-myeloma cellular immunity</article-title>. <source>Cancer Immunol Immunother.</source><year>2013</year>;<volume>62</volume>(<issue>1</issue>):<fpage>39</fpage>-<lpage>49</lpage>.<pub-id pub-id-type="pmid">22733396</pub-id></mixed-citation>
              </ref>
              <ref id="B15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cabeza-Cabrerizo</surname><given-names>M</given-names></string-name>, <string-name><surname>Cardoso</surname><given-names>A</given-names></string-name>, <string-name><surname>Minutti</surname><given-names>CM</given-names></string-name>, <string-name><surname>Pereira da Costa</surname><given-names>M</given-names></string-name>, <string-name><surname>Reis E Sousa</surname><given-names>C</given-names></string-name></person-group>. <article-title>Dendritic cells revisited</article-title>. <source>Annu Rev Immunol.</source><year>2021</year>;<volume>39</volume>(<issue>1</issue>): <fpage>131</fpage>-<lpage>166</lpage>.<pub-id pub-id-type="pmid">33481643</pub-id></mixed-citation>
              </ref>
              <ref id="B16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Santos</surname><given-names>PM</given-names></string-name>, <string-name><surname>Butterfield</surname><given-names>LH</given-names></string-name></person-group>. <article-title>Dendritic cell-based cancer vaccines</article-title>. <source>J Immunol.</source><year>2018</year>;<volume>200</volume>(<issue>2</issue>):<fpage>443</fpage>-<lpage>449</lpage>.<pub-id pub-id-type="pmid">29311386</pub-id></mixed-citation>
              </ref>
              <ref id="B17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ratzinger</surname><given-names>G</given-names></string-name>, <string-name><surname>Baggers</surname><given-names>J</given-names></string-name>, <string-name><surname>de Cos</surname><given-names>MA</given-names></string-name>, <etal/></person-group>. <article-title>Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells</article-title>. <source>J Immunol.</source><year>2004</year>;<volume>173</volume>(<issue>4</issue>):<fpage>2780</fpage>-<lpage>2791</lpage>.<pub-id pub-id-type="pmid">15294997</pub-id></mixed-citation>
              </ref>
              <ref id="B18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klechevsky</surname><given-names>E</given-names></string-name>, <string-name><surname>Morita</surname><given-names>R</given-names></string-name>, <string-name><surname>Liu</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells</article-title>. <source>Immunity.</source><year>2008</year>;<volume>29</volume>(<issue>3</issue>):<fpage>497</fpage>-<lpage>510</lpage>.<pub-id pub-id-type="pmid">18789730</pub-id></mixed-citation>
              </ref>
              <ref id="B19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Romano</surname><given-names>E</given-names></string-name>, <string-name><surname>Cotari</surname><given-names>JW</given-names></string-name>, <string-name><surname>Barreira da Silva</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1</article-title>. <source>Blood.</source><year>2012</year>;<volume>119</volume>(<issue>22</issue>):<fpage>5182</fpage>-<lpage>5190</lpage>.<pub-id pub-id-type="pmid">22510877</pub-id></mixed-citation>
              </ref>
              <ref id="B20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Banchereau</surname><given-names>J</given-names></string-name>, <string-name><surname>Thompson-Snipes</surname><given-names>L</given-names></string-name>, <string-name><surname>Zurawski</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming</article-title>. <source>Blood.</source><year>2012</year>;<volume>119</volume>(<issue>24</issue>):<fpage>5742</fpage>-<lpage>5749</lpage>.<pub-id pub-id-type="pmid">22535664</pub-id></mixed-citation>
              </ref>
              <ref id="B21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Banchereau</surname><given-names>J</given-names></string-name>, <string-name><surname>Palucka</surname><given-names>AK</given-names></string-name>, <string-name><surname>Dhodapkar</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine</article-title>. <source>Cancer Res.</source><year>2001</year>;<volume>61</volume>(<issue>17</issue>):<fpage>6451</fpage>-<lpage>6458</lpage>.<pub-id pub-id-type="pmid">11522640</pub-id></mixed-citation>
              </ref>
              <ref id="B22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chung</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Carvajal</surname><given-names>RD</given-names></string-name>, <string-name><surname>Postow</surname><given-names>MA</given-names></string-name>, <etal/></person-group>. <article-title>Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: results of a phase I vaccine trial</article-title>. <source>OncoImmunology.</source><year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>e1372081</fpage>.<pub-id pub-id-type="pmid">29296525</pub-id></mixed-citation>
              </ref>
              <ref id="B23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nair</surname><given-names>SK</given-names></string-name>, <string-name><surname>Boczkowski</surname><given-names>D</given-names></string-name>, <string-name><surname>Morse</surname><given-names>M</given-names></string-name>, <string-name><surname>Cumming</surname><given-names>RI</given-names></string-name>, <string-name><surname>Lyerly</surname><given-names>HK</given-names></string-name>, <string-name><surname>Gilboa</surname><given-names>E</given-names></string-name></person-group>. <article-title>Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA</article-title>. <source>Nat Biotechnol.</source><year>1998</year>;<volume>16</volume>(<issue>4</issue>):<fpage>364</fpage>-<lpage>369</lpage>.<pub-id pub-id-type="pmid">9555728</pub-id></mixed-citation>
              </ref>
              <ref id="B24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boczkowski</surname><given-names>D</given-names></string-name>, <string-name><surname>Nair</surname><given-names>SK</given-names></string-name>, <string-name><surname>Nam</surname><given-names>JH</given-names></string-name>, <string-name><surname>Lyerly</surname><given-names>HK</given-names></string-name>, <string-name><surname>Gilboa</surname><given-names>E</given-names></string-name></person-group>. <article-title>Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells</article-title>. <source>Cancer Res.</source><year>2000</year>;<volume>60</volume>(<issue>4</issue>):<fpage>1028</fpage>-<lpage>1034</lpage>.<pub-id pub-id-type="pmid">10706120</pub-id></mixed-citation>
              </ref>
              <ref id="B25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muul</surname><given-names>LM</given-names></string-name>, <string-name><surname>Tuschong</surname><given-names>LM</given-names></string-name>, <string-name><surname>Soenen</surname><given-names>SL</given-names></string-name>, <etal/></person-group>. <article-title>Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial</article-title>. <source>Blood.</source><year>2003</year>;<volume>101</volume>(<issue>7</issue>):<fpage>2563</fpage>-<lpage>2569</lpage>.<pub-id pub-id-type="pmid">12456496</pub-id></mixed-citation>
              </ref>
              <ref id="B26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hacein-Bey-Abina</surname><given-names>S</given-names></string-name>, <string-name><surname>Von Kalle</surname><given-names>C</given-names></string-name>, <string-name><surname>Schmidt</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1</article-title>. <source>Science.</source><year>2003</year>;<volume>302</volume>(<issue>5644</issue>):<fpage>415</fpage>-<lpage>419</lpage>.<pub-id pub-id-type="pmid">14564000</pub-id></mixed-citation>
              </ref>
              <ref id="B27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jungbluth</surname><given-names>AA</given-names></string-name>, <string-name><surname>Ely</surname><given-names>S</given-names></string-name>, <string-name><surname>DiLiberto</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation</article-title>. <source>Blood.</source><year>2005</year>;<volume>106</volume>(<issue>1</issue>):<fpage>167</fpage>-<lpage>174</lpage>.<pub-id pub-id-type="pmid">15761016</pub-id></mixed-citation>
              </ref>
              <ref id="B28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tinguely</surname><given-names>M</given-names></string-name>, <string-name><surname>Jenni</surname><given-names>B</given-names></string-name>, <string-name><surname>Knights</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome</article-title>. <source>Cancer Sci.</source><year>2008</year>;<volume>99</volume>(<issue>4</issue>):<fpage>720</fpage>-<lpage>725</lpage>.<pub-id pub-id-type="pmid">18307538</pub-id></mixed-citation>
              </ref>
              <ref id="B29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tyler</surname><given-names>EM</given-names></string-name>, <string-name><surname>Jungbluth</surname><given-names>AA</given-names></string-name>, <string-name><surname>O’Reilly</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Koehne</surname><given-names>G</given-names></string-name></person-group>. <article-title>WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions</article-title>. <source>Blood.</source><year>2013</year>;<volume>121</volume>(<issue>2</issue>):<fpage>308</fpage>-<lpage>317</lpage>.<pub-id pub-id-type="pmid">23160468</pub-id></mixed-citation>
              </ref>
              <ref id="B30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nardiello</surname><given-names>T</given-names></string-name>, <string-name><surname>Jungbluth</surname><given-names>AA</given-names></string-name>, <string-name><surname>Mei</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin</article-title>. <source>Clin Cancer Res.</source><year>2011</year>;<volume>17</volume>(<issue>13</issue>):<fpage>4309</fpage>-<lpage>4319</lpage>.<pub-id pub-id-type="pmid">21565982</pub-id></mixed-citation>
              </ref>
              <ref id="B31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hatta</surname><given-names>Y</given-names></string-name>, <string-name><surname>Takeuchi</surname><given-names>J</given-names></string-name>, <string-name><surname>Saitoh</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>WT1 expression level and clinical factors in multiple myeloma</article-title>. <source>J Exp Clin Cancer Res.</source><year>2005</year>;<volume>24</volume>(<issue>4</issue>):<fpage>595</fpage>-<lpage>599</lpage>.<pub-id pub-id-type="pmid">16471322</pub-id></mixed-citation>
              </ref>
              <ref id="B32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tyler</surname><given-names>EM</given-names></string-name>, <string-name><surname>Jungbluth</surname><given-names>AA</given-names></string-name>, <string-name><surname>O’Reilly</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Koehne</surname><given-names>G</given-names></string-name></person-group>. <article-title>Wilms’ tumor 1 protein-specific T-cell responses in high-risk multiple myeloma patients undergoing T-cell depleted allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusion</article-title>. <source>Blood</source>. <year>2013</year>;<volume>121</volume>(<issue>2</issue>):<fpage>308</fpage>-<lpage>317</lpage>.<pub-id pub-id-type="pmid">23160468</pub-id></mixed-citation>
              </ref>
              <ref id="B33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tyler</surname><given-names>EM</given-names></string-name>, <string-name><surname>Jungbluth</surname><given-names>AA</given-names></string-name>, <string-name><surname>Gnjatic</surname><given-names>S</given-names></string-name>, <string-name><surname>O’Reilly</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Koehne</surname><given-names>G</given-names></string-name></person-group>. <article-title>Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma</article-title>. <source>Cancer Immunol Res.</source><year>2014</year>;<volume>2</volume>(<issue>6</issue>):<fpage>547</fpage>-<lpage>558</lpage>.<pub-id pub-id-type="pmid">24894092</pub-id></mixed-citation>
              </ref>
              <ref id="B34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Azuma</surname><given-names>T</given-names></string-name>, <string-name><surname>Otsuki</surname><given-names>T</given-names></string-name>, <string-name><surname>Kuzushima</surname><given-names>K</given-names></string-name>, <string-name><surname>Froelich</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Fujita</surname><given-names>S</given-names></string-name>, <string-name><surname>Yasukawa</surname><given-names>M</given-names></string-name></person-group>. <article-title>Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes</article-title>. <source>Clin Cancer Res.</source><year>2004</year>;<volume>10</volume>(<issue>21</issue>):<fpage>7402</fpage>-<lpage>7412</lpage>.<pub-id pub-id-type="pmid">15534117</pub-id></mixed-citation>
              </ref>
              <ref id="B35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tsuboi</surname><given-names>A</given-names></string-name>, <string-name><surname>Oka</surname><given-names>Y</given-names></string-name>, <string-name><surname>Nakajima</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma</article-title>. <source>Int J Hematol.</source><year>2007</year>;<volume>86</volume>(<issue>5</issue>):<fpage>414</fpage>-<lpage>417</lpage>.<pub-id pub-id-type="pmid">18192109</pub-id></mixed-citation>
              </ref>
              <ref id="B36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yao</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Begg</surname><given-names>CB</given-names></string-name>, <string-name><surname>Livingston</surname><given-names>PO</given-names></string-name></person-group>. <article-title>Optimal sample size for a series of pilot trials of new agents</article-title>. <source>Biometrics.</source><year>1996</year>;<volume>52</volume>(<issue>3</issue>):<fpage>992</fpage>-<lpage>1001</lpage>.<pub-id pub-id-type="pmid">8805764</pub-id></mixed-citation>
              </ref>
              <ref id="B37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jungbluth</surname><given-names>AA</given-names></string-name>, <string-name><surname>Chen</surname><given-names>YT</given-names></string-name>, <string-name><surname>Busam</surname><given-names>KJ</given-names></string-name>, <etal/></person-group>. <article-title>CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues</article-title>. <source>Int J Cancer.</source><year>2002</year>;<volume>99</volume>(<issue>6</issue>):<fpage>839</fpage>-<lpage>845</lpage>.<pub-id pub-id-type="pmid">12115486</pub-id></mixed-citation>
              </ref>
              <ref id="B38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chung</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Romano</surname><given-names>E</given-names></string-name>, <string-name><surname>Pronschinske</surname><given-names>KB</given-names></string-name>, <etal/></person-group>. <article-title>Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy</article-title>. <source>J Transl Med.</source><year>2013</year>;<volume>11</volume>(<issue>1</issue>):<fpage>166</fpage>.<pub-id pub-id-type="pmid">23837662</pub-id></mixed-citation>
              </ref>
              <ref id="B39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roshal</surname><given-names>M</given-names></string-name>, <string-name><surname>Flores-Montero</surname><given-names>JA</given-names></string-name>, <string-name><surname>Gao</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods</article-title>. <source>Blood Adv.</source><year>2017</year>;<volume>1</volume>(<issue>12</issue>):<fpage>728</fpage>-<lpage>732</lpage>.<pub-id pub-id-type="pmid">29296716</pub-id></mixed-citation>
              </ref>
              <ref id="B40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muraro</surname><given-names>PA</given-names></string-name>, <string-name><surname>Robins</surname><given-names>H</given-names></string-name>, <string-name><surname>Malhotra</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>T cell repertoire following autologous stem cell transplantation for multiple sclerosis</article-title>. <source>J Clin Invest.</source><year>2014</year>;<volume>124</volume>(<issue>3</issue>):<fpage>1168</fpage>-<lpage>1172</lpage>.<pub-id pub-id-type="pmid">24531550</pub-id></mixed-citation>
              </ref>
              <ref id="B41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sheikh</surname><given-names>N</given-names></string-name>, <string-name><surname>Cham</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Clonotypic diversification of intratumoral T cells following sipuleucel-T treatment in prostate cancer subjects</article-title>. <source>Cancer Res.</source><year>2016</year>;<volume>76</volume>(<issue>13</issue>):<fpage>3711</fpage>-<lpage>3718</lpage>.<pub-id pub-id-type="pmid">27216195</pub-id></mixed-citation>
              </ref>
              <ref id="B42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Postow</surname><given-names>MA</given-names></string-name>, <string-name><surname>Manuel</surname><given-names>M</given-names></string-name>, <string-name><surname>Wong</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma</article-title>. <source>J Immunother Cancer.</source><year>2015</year>;<volume>3</volume>(<issue>1</issue>):<fpage>23</fpage>.<pub-id pub-id-type="pmid">26085931</pub-id></mixed-citation>
              </ref>
              <ref id="B43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ratta</surname><given-names>M</given-names></string-name>, <string-name><surname>Fagnoni</surname><given-names>F</given-names></string-name>, <string-name><surname>Curti</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6</article-title>. <source>Blood.</source><year>2002</year>;<volume>100</volume>(<issue>1</issue>): <fpage>230</fpage>-<lpage>237</lpage>.<pub-id pub-id-type="pmid">12070032</pub-id></mixed-citation>
              </ref>
              <ref id="B44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kukreja</surname><given-names>A</given-names></string-name>, <string-name><surname>Hutchinson</surname><given-names>A</given-names></string-name>, <string-name><surname>Dhodapkar</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Enhancement of clonogenicity of human multiple myeloma by dendritic cells</article-title>. <source>J Exp Med.</source><year>2006</year>; <volume>203</volume>(<issue>8</issue>):<fpage>1859</fpage>-<lpage>1865</lpage>.<pub-id pub-id-type="pmid">16880256</pub-id></mixed-citation>
              </ref>
              <ref id="B45">
                <label>45.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leone</surname><given-names>P</given-names></string-name>, <string-name><surname>Berardi</surname><given-names>S</given-names></string-name>, <string-name><surname>Frassanito</surname><given-names>MA</given-names></string-name>, <etal/></person-group>. <article-title>Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8<sup>+</sup> T-cell killing</article-title>. <source>Blood.</source><year>2015</year>;<volume>126</volume>(<issue>12</issue>):<fpage>1443</fpage>-<lpage>1451</lpage>.<pub-id pub-id-type="pmid">26185130</pub-id></mixed-citation>
              </ref>
              <ref id="B46">
                <label>46.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Racanelli</surname><given-names>V</given-names></string-name>, <string-name><surname>Leone</surname><given-names>P</given-names></string-name>, <string-name><surname>Frassanito</surname><given-names>MA</given-names></string-name>, <etal/></person-group>. <article-title>Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8<sup>+</sup> T cells and characterize the progression of MGUS to multiple myeloma</article-title>. <source>Blood.</source><year>2010</year>;<volume>115</volume>(<issue>6</issue>):<fpage>1185</fpage>-<lpage>1193</lpage>.<pub-id pub-id-type="pmid">20008301</pub-id></mixed-citation>
              </ref>
              <ref id="B47">
                <label>47.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Görgün</surname><given-names>GT</given-names></string-name>, <string-name><surname>Whitehill</surname><given-names>G</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>JL</given-names></string-name>, <etal/></person-group>. <article-title>Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans</article-title>. <source>Blood.</source><year>2013</year>;<volume>121</volume>(<issue>15</issue>):<fpage>2975</fpage>-<lpage>2987</lpage>.<pub-id pub-id-type="pmid">23321256</pub-id></mixed-citation>
              </ref>
              <ref id="B48">
                <label>48.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Braga</surname><given-names>WM</given-names></string-name>, <string-name><surname>da Silva</surname><given-names>BR</given-names></string-name>, <string-name><surname>de Carvalho</surname><given-names>AC</given-names></string-name>, <etal/></person-group>. <article-title>FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells</article-title>. <source>Cancer Immunol Immunother.</source><year>2014</year>;<volume>63</volume>(<issue>11</issue>):<fpage>1189</fpage>-<lpage>1197</lpage>.<pub-id pub-id-type="pmid">25099367</pub-id></mixed-citation>
              </ref>
              <ref id="B49">
                <label>49.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Asimakopoulos</surname><given-names>F</given-names></string-name>, <string-name><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name><surname>Denu</surname><given-names>RA</given-names></string-name>, <etal/></person-group>. <article-title>Macrophages in multiple myeloma: emerging concepts and therapeutic implications</article-title>. <source>Leuk Lymphoma.</source><year>2013</year>;<volume>54</volume>(<issue>10</issue>):<fpage>2112</fpage>-<lpage>2121</lpage>.<pub-id pub-id-type="pmid">23432691</pub-id></mixed-citation>
              </ref>
              <ref id="B50">
                <label>50.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Minnie</surname><given-names>SA</given-names></string-name>, <string-name><surname>Kuns</surname><given-names>RD</given-names></string-name>, <string-name><surname>Gartlan</surname><given-names>KH</given-names></string-name>, <etal/></person-group>. <article-title>Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade</article-title> [published correction appears in <italic toggle="yes">Blood</italic>. 2019;134(21):1878]. <source>Blood.</source>
<year>2018</year>;<volume>132</volume>(<issue>16</issue>):<fpage>1675</fpage>-<lpage>1688</lpage>.<pub-id pub-id-type="pmid">30154111</pub-id></mixed-citation>
              </ref>
              <ref id="B51">
                <label>51.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parmar</surname><given-names>H</given-names></string-name>, <string-name><surname>Gertz</surname><given-names>M</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>EI</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name><surname>Kourelis</surname><given-names>TV</given-names></string-name></person-group>. <article-title>Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma</article-title>. <source>Blood Adv.</source><year>2021</year>;<volume>5</volume>(<issue>7</issue>):<fpage>1797</fpage>-<lpage>1804</lpage>.<pub-id pub-id-type="pmid">33787859</pub-id></mixed-citation>
              </ref>
              <ref id="B52">
                <label>52.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Visram</surname><given-names>A</given-names></string-name>, <string-name><surname>Kourelis</surname><given-names>T</given-names></string-name>, <string-name><surname>Dasari</surname><given-names>S</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>E</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>SK</given-names></string-name></person-group>. <article-title>Describing the cellular and humoral immune tumor microenvironment and malignant transcriptome across the multiple myeloma disease spectrum</article-title>. <source>Blood.</source><year>2020</year>;<volume>136</volume>(<issue>suppl 1</issue>):<fpage>39</fpage>-<lpage>40</lpage>.</mixed-citation>
              </ref>
              <ref id="B53">
                <label>53.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shah</surname><given-names>N</given-names></string-name>, <string-name><surname>Chari</surname><given-names>A</given-names></string-name>, <string-name><surname>Scott</surname><given-names>E</given-names></string-name>, <string-name><surname>Mezzi</surname><given-names>K</given-names></string-name>, <string-name><surname>Usmani</surname><given-names>SZ</given-names></string-name></person-group>. <article-title>B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches</article-title>. <source>Leukemia.</source><year>2020</year>;<volume>34</volume>(<issue>4</issue>):<fpage>985</fpage>-<lpage>1005</lpage>.<pub-id pub-id-type="pmid">32055000</pub-id></mixed-citation>
              </ref>
              <ref id="B54">
                <label>54.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akahori</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name><surname>Yoneyama</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination</article-title>. <source>Blood.</source><year>2018</year>;<volume>132</volume>(<issue>11</issue>):<fpage>1134</fpage>-<lpage>1145</lpage>.<pub-id pub-id-type="pmid">30045840</pub-id></mixed-citation>
              </ref>
              <ref id="B55">
                <label>55.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reinhard</surname><given-names>K</given-names></string-name>, <string-name><surname>Rengstl</surname><given-names>B</given-names></string-name>, <string-name><surname>Oehm</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors</article-title>. <source>Science.</source><year>2020</year>;<volume>367</volume>(<issue>6476</issue>):<fpage>446</fpage>-<lpage>453</lpage>.<pub-id pub-id-type="pmid">31896660</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
